Alpha-Synuclein

GWB-DA182E

A synthetic peptide corresponding to residues on the N-terminus of human Alpha-synuclein was used as an immunogen.

WB: 1:1 000 - 10 000ICC: 1:50 - 100. Alpha-synuclein is expressed predominantly in brain where it is concentrated in presynaptic nerve terminals (1). The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson\' s disease (PD) dementia with Lewy bodies (DLB) and multiple system atrophy collectively referred to as synucleinopathies. Phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro and these results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders (2). Parkinson\' s disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. It is hypothesized that parkin and alpha-synculein interact functionally namely that parkin ubiquitinates alpha-synuclein normally and that this process is altered in autosomal recessive PD (3). 1. Qing H Wong W McGeer EG et al Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications Biochem Biophys Res Commun 387 (2009) 149-52[Application: WB]1. Jakes R et al. FEBS Lett. 345(1):27-32 1994. 2. Fujiwara H et al. Nat Cell Biol 4(2):160-4 2002. 3. Shimura H et al. Science 293(5528):263-9 2001. 4. Manufactured under U. S. Patents No. 5 675 063 and 7 429 487